



ASX release

7 July 2010

US\$1.77 million new pharmaceutical contract
US\$2.9m new contracts in past three months

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressures and arterial stiffness noninvasively, today announced that it has signed a new agreement to supply SphygmoCor systems and clinical trial support services to a major international pharmaceutical company. The US\$1.77m contract is with an existing AtCor customer.

Duncan Ross, CEO of AtCor Medical said, “AtCor has closed new contracts valued at US\$2.9 million since March, demonstrating the resurgence of the pharmaceutical trial sector since US healthcare reform legislation was signed . This significant contract confirms AtCor’s market position as the leading provider of noninvasive central blood pressure and arterial stiffness measurement in clinical trials. It also shows AtCor’s reputation for high levels of customer satisfaction is being rewarded through expanded business with long-term clients.”

Mr. Ross added, “Scientific publications continue to reinforce the importance of using central blood pressure as a measurement. This mounting body of evidence helps to drive our sales to pharmaceutical businesses and supports accelerated adoption of SphygmoCor in clinical practice. Understanding a drug’s effect on central pressure is vitally important in assessing efficacy and in assuring drug safety. It is equally important in patient care. “

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central blood pressure non-invasively. The company’s SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 2,100 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company’s technology has been featured in hundreds of peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au